Shares of medical device company CooperCompanies (NASDAQ:COO)
fell 3.2% in the afternoon session after Rothschild & Co Redburn lowered its price target on the stock to $92 from $95.
Looking back on medical devices & supplies - diversified stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including CooperCompanies (NASDAQ:COO) and its peers.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.
Shares of medical device company CooperCompanies (NASDAQ:COO)
fell 12.4% in the afternoon session after the company reported mixed second-quarter 2025 results, with its forecast for the upcoming quarter falling short of Wall Street's expectations.
Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Medical device company CooperCompanies (NASDAQ:COO) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 5.7% year on year to $1.06 billion. On the other hand, next quarter’s revenue guidance of $1.06 billion was less impressive, coming in 2.8% below analysts’ estimates. Its non-GAAP profit of $1.10 per share was 3% above analysts’ consensus estimates.
Medical device company CooperCompanies (NASDAQ:COO) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 5.7% year on year to $1.06 billion. On the other hand, next quarter’s revenue guidance of $1.06 billion was less impressive, coming in 2.8% below analysts’ estimates. Its non-GAAP profit of $1.10 per share was 3% above analysts’ consensus estimates.
